Here are the 10-K annual reports from Bolt Biotherapeutics, Inc. (BOLT) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow BOLT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BOLT filings page.
Bolt Biotherapeutics files its annual report outlining a focused immuno-oncology strategy built around its Boltbody ISAC platform. The company is prioritizing clinical development of BDC-4182, a claudin 18.2-targeting ISAC in a first-in-human Phase 1 trial for gastric/gastroesophageal junction cancer, while other pipeline programs are on hold pending funding or partnerships.
Bolt highlights collaborations with Toray, Genmab and Innovent, an exclusive license to core ISAC technology from Stanford, and a patent estate expected to run into the 2040s. As of June 30, 2025, non-affiliate common stock held a market value of about $7.3 million, and as of March 6, 2026, 1,921,567 shares of common stock were outstanding. The company reports only 23 employees and emphasizes that it has a limited operating history, significant accumulated losses, substantial future funding needs, and numerous clinical, regulatory, manufacturing, competition, reimbursement and macroeconomic risks that could affect its ability to commercialize any product candidates and maintain its stock price.